Received Dec 18, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| HPVX | HPV (NO BRAND NAME) | UNKNOWN MANUFACTURER | UNK | — | — |
| HPVX | HPV (NO BRAND NAME) | UNKNOWN MANUFACTURER | UNK | — | — |
| UNK | VACCINE NOT SPECIFIED (NO BRAND NAME) | UNKNOWN MANUFACTURER | UNK | — | — |
| UNK | VACCINE NOT SPECIFIED (NO BRAND NAME) | UNKNOWN MANUFACTURER | UNK | — | — |
no adverse event; Product origin unknown; the patient received unspecified HPV vaccine at age 7 and subsequent one 6 months later; This spontaneous report was received from a Physician and refers to a 7-year-old male patient. The patient's medical history was not reported. The patient's concurrent conditions were not reported. Concomitant therapies were not reported. On approximately 2023, the patient started therapy with Human Papillomavirus 9-valent Vaccine, Recombinant (GARDASIL 9), (lot # and expiration date were not reported) or Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant Vaccine (GARDASIL), (lot # and expiration date were not reported) (lot # and expiration date were not reported) (reported as HPV vaccination, Product origin unknown) at age 7, and on approximately 2023 (6 months later) the patient received subsequent dose of Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant Vaccine (GARDASIL), (lot # and expiration date were not reported) or Human Papillomavirus 9-valent Vaccine, Recombinant (GARDASIL9), for the treatment of prophylaxis. No adverse event was reported.